Literature DB >> 12436446

Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998.

Pamela J Mink1, Mark E Sherman, Susan S Devesa.   

Abstract

BACKGROUND: Malignant tumors of the ovary are the leading cause of death from gynecologic malignancies in the United States. Population-based incidence data for these neoplasms by histopathologic type and race are limited. Variation in rates may provide clues for future etiologic studies.
METHODS: The authors performed a detailed, population-based analysis of U.S. incidence rates by histologic type, race, and age for invasive ovarian tumors that were diagnosed during 1978-1998 and for borderline ovarian tumors that were diagnosed during 1992-1998 using data from the U.S. Surveillance, Epidemiology, and End Results (SEER) Program.
RESULTS: White women had significantly higher rates compared with black women of all types of epithelial tumors, with the white:black rate ratios ranging from 1.23 to 2.56. Black women had higher rates of gonadal stromal tumors. Among both white women and black women, total carcinoma rates did not change greatly from 1978-1982 to 1995-1998. Among white women, the reported incidence rates for invasive serous, endometrioid, and clear cell tumors increased during 1978-1998, whereas the rates of mucinous; papillary, not otherwise specified (NOS); and other epithelial tumors declined. Among black women, the reported rates of papillary, NOS tumors decreased significantly, whereas the rates of other tumor types fluctuated. Incidence rates of borderline ovarian tumors were higher among white women compared with black women and did not change significantly during 1992-1998. Serous and mucinous tumors were the predominant tumors reported for women age < 45 years, whereas serous; papillary, NOS; and other epithelial tumors predominated among older women.
CONCLUSIONS: Incidence rates for malignant ovarian tumors have remained relatively stable, with higher rates for white women compared with black women. The reported rates for some specific histopathologic tumor types have changed over time, in part reflecting more specific pathologic classification. The possible effect of shifting exposure prevalence on incidence patterns warrants further study.

Entities:  

Mesh:

Year:  2002        PMID: 12436446     DOI: 10.1002/cncr.10935

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race/Ethnicity and Histologic Subtypes.

Authors:  Hyo K Park; Julie J Ruterbusch; Michele L Cote
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-07-27       Impact factor: 4.254

2.  Ovarian Sex Cord-Stromal Tumors.

Authors:  Kris Ann P Schultz; Anne K Harris; Dominik T Schneider; Robert H Young; Jubilee Brown; David M Gershenson; Louis P Dehner; D Ashley Hill; Yoav H Messinger; A Lindsay Frazier
Journal:  J Oncol Pract       Date:  2016-10       Impact factor: 3.840

3.  A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.

Authors:  Charlotte Gerd Hannibal; Russell Vang; Jette Junge; Kirsten Frederiksen; Anette Kjaerbye-Thygesen; Klaus Kaae Andersen; Ann Tabor; Robert J Kurman; Susanne K Kjaer
Journal:  Gynecol Oncol       Date:  2014-06-10       Impact factor: 5.482

4.  Mumps and ovarian cancer: modern interpretation of an historic association.

Authors:  Daniel W Cramer; Allison F Vitonis; Simone P Pinheiro; John R McKolanis; Raina N Fichorova; Kevin E Brown; Todd F Hatchette; Olivera J Finn
Journal:  Cancer Causes Control       Date:  2010-06-18       Impact factor: 2.506

Review 5.  Interventions for the treatment of borderline ovarian tumours.

Authors:  Olusola Faluyi; Melanie Mackean; Charlie Gourley; Andrew Bryant; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2010-09-08

6.  Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib.

Authors:  Masafumi Koshiyama; Noriomi Matsumura; Tsukasa Baba; Ken Yamaguchi; Yumiko Yoshioka; Ikuo Konishi
Journal:  Cancer Biol Ther       Date:  2013-10-21       Impact factor: 4.742

7.  Detection of cancer-specific markers amid massive mass spectral data.

Authors:  Wei Zhu; Xuena Wang; Yeming Ma; Manlong Rao; James Glimm; John S Kovach
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

8.  Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial.

Authors:  Ashley S Felix; Louise A Brinton; D Scott McMeekin; William T Creasman; David Mutch; David E Cohn; Joan L Walker; Richard G Moore; Levi S Downs; Robert A Soslow; Richard Zaino; Mark E Sherman
Journal:  J Natl Cancer Inst       Date:  2015-06-18       Impact factor: 13.506

9.  Nationwide population-based study of prevalence and trend of borderline ovarian tumors in the Republic of Korea.

Authors:  Yung-Taek Ouh; Dongwoo Kang; Hoseob Kim; Jae Kwan Lee; Jin Hwa Hong
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

10.  Histologic distribution of borderline ovarian tumors worldwide: a systematic review.

Authors:  Taejong Song; Yoo-Young Lee; Chel Hun Choi; Tae-Joong Kim; Jeong-Won Lee; Duk-Soo Bae; Byoung-Gie Kim
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.